-
Zhonghua Xue Ye Xue Za Zhi = Zhonghua... Jan 2019To analyze the clinical outcome and the prognostic factor in pediatric patients with core binding factor-acute myeloid leukemia (CBF-AML). A total of 121 newly...
To analyze the clinical outcome and the prognostic factor in pediatric patients with core binding factor-acute myeloid leukemia (CBF-AML). A total of 121 newly diagnosed pediatric CBF-AML patients enrolled from Aug. 2005 to Sep. 2017 were retrospectively reviewed. Cumulative incidence of relapse (CIR), event-free survival (EFS) and overall survival (OS) rates were estimated by Kaplan-Meier method and prognostic factors were evaluated by Cox regression with SPSS. Of the 121 patients, 120 patients were assessed for bone marrow remission after induction chemotherapy. 100 cases (83.3%) achieved complete remission (CR) after the first course of chemotherapy. 119 cases (99.2%) achieved CR after the second course of chemotherapy. Of the 121 patients, 13 patients (10.7%) had recurrence with the median interval of recurrence as 13.8 months (3.7 to 58.8 months). 17 patients (14.0%) died. The CIR, EFS and OS at 3 years were 12.7%, 77.5% and 82.8%, respectively. The factors including age at diagnosis, sex, initial WBC count, presence of extramedullary leukemia, C-KIT expression, additional chromosomal abnormalities, and CR after the first course of chemotherapy were analyzed by multivariate regression analysis of Cox. Multivariate analysis identified that additional chromosomal abnormalities was the only independent risk factor affecting OS (=4.289, 95% 1.070-17.183, =0.040). Pediatric CBF-AML was a unique setting of prognostic subtypes. Chemotherapy produced good responses. Additional chromosomal abnormalities was the only independent risk factor for OS in pediatric CBF-AML.
Topics: Child; Core Binding Factors; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Prognosis; Remission Induction; Retrospective Studies
PubMed: 30704229
DOI: 10.3760/cma.j.issn.0253-2727.2019.01.010 -
Annals of Surgical Oncology Jul 2023
Topics: Humans; Thymoma; Prognosis; Thymus Neoplasms; Neoplasm Staging; Retrospective Studies
PubMed: 37067743
DOI: 10.1245/s10434-023-13445-z -
Oncotarget Aug 2016As there are millions of cancer deaths every year, it is of great value to identify applicable prognostic biomarkers. As an important alarm, the prognostic role of high... (Meta-Analysis)
Meta-Analysis Review
As there are millions of cancer deaths every year, it is of great value to identify applicable prognostic biomarkers. As an important alarm, the prognostic role of high mobility group box 1 (HMGB1) in cancer remains controversial. We aim to assess the association of HMGB1 expression with prognosis in cancer patients. Systematic literature searches of PubMed, Embase and Web of Science databases were performed for eligible studies of HMGB1 as prognostic factor in cancer. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to evaluate the influence of HMGB1 expression on overall survival (OS) and progression-free survival (PFS) in cancer patients. 18 studies involving 11 different tumor types were included in meta-analysis. HMGB1 overexpression was significantly associated with poorer OS (HR: 1.99; 95% CI, 1.71-2.31) and PFS (HR: 2.26; 95% CI, 1.65-3.10) irrespective of cancer types including gastric cancer, colorectal cancer, hepatocellular carcinoma, pancreatic cancer, nasopharyngeal carcinoma, head and neck squamous-cell carcinoma, esophageal cancer, malignant pleural mesothelioma, bladder cancer, prostate cancer, and cervical carcinoma. Subgroup analyses indicated geographical area and size of studies did not affect the prognostic effects of HMGB1 for OS. Morever, HMGB1 overexpression had a consistent correlation with poorer OS when detected by immunohistochemistry in tissues and enzyme-linked immunosorbent assay in serum, whereas the correlation did not exist by quantitative real-time reverse-transcription polymerase chain reaction in tissues. HMGB1 overexpression is associated with poorer prognosis in patients with various types of cancer, suggesting that it is a prognostic factor and potential biomarker for survival in cancer.
Topics: Biomarkers, Tumor; Disease-Free Survival; Gene Expression Regulation, Neoplastic; Geography; HMGB1 Protein; Humans; Neoplasms; Prognosis; Proportional Hazards Models; Treatment Outcome
PubMed: 27391431
DOI: 10.18632/oncotarget.10413 -
Colorectal Disease : the Official... May 2018The impact of quality of surgery, colorectal surgical specialization, training and expertise has been far greater on survival outcomes than adjuvant and neoadjuvant... (Review)
Review
The impact of quality of surgery, colorectal surgical specialization, training and expertise has been far greater on survival outcomes than adjuvant and neoadjuvant therapies. The review of the evidence by Professor Martling and expert discussion addresses the evidence base and the crucial importance of the surgeon as a prognostic factor, and how this has been relatively neglected in comparison to other resources invested in improving the treatment of colorectal cancer.
Topics: Clinical Competence; Colorectal Neoplasms; Colorectal Surgery; Female; Hospitals, High-Volume; Humans; Male; Outcome Assessment, Health Care; Physician's Role; Prognosis; Specialization; Surgeons; Survival Analysis; Treatment Outcome
PubMed: 29878669
DOI: 10.1111/codi.14076 -
PLoS Medicine 2013Prognostic factor research aims to identify factors associated with subsequent clinical outcome in people with a particular disease or health condition. In this article,... (Review)
Review
Prognostic factor research aims to identify factors associated with subsequent clinical outcome in people with a particular disease or health condition. In this article, the second in the PROGRESS series, the authors discuss the role of prognostic factors in current clinical practice, randomised trials, and developing new interventions, and explain why and how prognostic factor research should be improved.
Topics: Biomarkers; Biomedical Research; Decision Support Techniques; Disease Progression; Health Services Research; Humans; Predictive Value of Tests; Prognosis; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Risk Factors; Treatment Outcome
PubMed: 23393429
DOI: 10.1371/journal.pmed.1001380 -
Gastroenterology Apr 2020
Topics: Anticoagulants; Humans; Incidence; Neoplasms; Pancreatic Neoplasms; Prognosis; Venous Thromboembolism
PubMed: 32061863
DOI: 10.1053/j.gastro.2020.02.017 -
Journal of Cancer Research and... 2022
Topics: Disease-Free Survival; Humans; Metabolic Syndrome; Neoplasms; Prognosis
PubMed: 36149193
DOI: 10.4103/jcrt.JCRT_323_19 -
International Journal of Surgery... Aug 2019
Topics: Albumins; Alkaline Phosphatase; Humans; Lung Neoplasms; Prognosis; Propensity Score; Prospective Studies
PubMed: 31336171
DOI: 10.1016/j.ijsu.2019.07.015 -
The Annals of Thoracic Surgery Aug 2020
Topics: Cardiopulmonary Bypass; Humans; Morbidity; Postoperative Period; Prognosis; Thrombocytopenia
PubMed: 32147417
DOI: 10.1016/j.athoracsur.2020.01.068 -
Thoracic Cancer Feb 2023Tumor size and consolidation-to-tumor ratio (CTR) are crucial for non-small cell lung cancer (NSCLC) prognosis. However, the optimal CTR cutoff remains unclear. Whether... (Review)
Review
BACKGROUND
Tumor size and consolidation-to-tumor ratio (CTR) are crucial for non-small cell lung cancer (NSCLC) prognosis. However, the optimal CTR cutoff remains unclear. Whether tumor size and CTR are independent prognostic factors for part-solid NSCLC is under debate. Here, we aimed to evaluate the prognostic impacts of CTR and tumor size on NSCLC, especially on part-solid NSCLC.
METHODS
We reviewed 1366 clinical T1 NSCLC patients who underwent surgical treatment. Log-rank test and Cox regression analyses were adopted for prognostic evaluation. The "surv_cutpoint" function was used to identify the optimal CTR and tumor size cutoff values.
RESULTS
There were 416, 510, and 440 subjects with pure ground-glass opacity (pGGO), part-solid, and pure solid nodules. The 5-year overall survival (disease-free survival) for patients with pGGO, part-solid, and pure solid nodules were 99.5% (99.5%), 97.3% (95.8%), and 90.4% (78.9%), respectively. Multivariate Cox regression analysis indicated that CTR was an independent prognostic factor for the whole patients, and the optimal CTR cutoff was 0.99. However, for part-solid NSCLC, CTR was not independently associated with survival, even if categorized by the optimal cutoffs. The predicted optimal cutoffs of total tumor size and solid component size were 2.4 and 1.4 cm for part-solid NSCLC. Total tumor size (HR = 6.21, 95% CI: 1.58-24.34, p = 0.009) and solid component size (HR = 2.27, 95% CI: 1.04-5.92, p = 0.045) grouped by the cutoffs were significantly associated with part-solid NSCLC prognosis.
CONCLUSIONS
CTR was an independent prognostic factor for the whole NSCLC, but not for the part-solid NSCLC. Tumor size was still meaningful for part-solid NSCLC.
Topics: Humans; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Prognosis; Neoplasm Staging; Tomography, X-Ray Computed; Retrospective Studies
PubMed: 36578128
DOI: 10.1111/1759-7714.14788